Skip to main
ORKA
ORKA logo

ORKA Stock Forecast & Price Target

ORKA Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 63%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oruka Therapeutics Inc is poised for significant growth due to its innovative lead and co-lead programs, ORKA-001 and ORKA-002, which target key inflammatory pathways in psoriasis and other conditions, presenting lucrative market opportunities. The preclinical data for ORKA-001 suggests a substantially longer half-life compared to established competitors, hinting at potential advantages in dosing frequency that could enhance patient compliance and market acceptance. Furthermore, the successful advance of ORKA-002 into clinical stages reflects strong confidence in the therapeutic potential of Oruka’s pipeline, positioning the company favorably in the competitive landscape of biopharmaceuticals.

Bears say

The financial outlook for Oruka Therapeutics Inc appears negative due to several substantial risks associated with its lead and co-lead drug programs, ORKA-001 and ORKA-002. Key concerns include the potential inability to advance these programs into pivotal trials in a timely manner, as well as the possibility of failing to demonstrate compelling efficacy in crucial psoriasis and psoriatic arthritis trials. Additionally, delays in regulatory filings and a competitive landscape among immunology therapeutics could hinder market uptake, further exacerbating the company's financial challenges and potentially leading to long-term dilution risks for shareholders.

ORKA has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 63% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oruka Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oruka Therapeutics Inc (ORKA) Forecast

Analysts have given ORKA a Buy based on their latest research and market trends.

According to 8 analysts, ORKA has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oruka Therapeutics Inc (ORKA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.